146 related articles for article (PubMed ID: 35574617)
1. Plasminogen Activator Inhibitor-1 Levels in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Alsharoh H; Ismaiel A; Leucuta DC; Popa SL; Dumitrascu DL
J Gastrointestin Liver Dis; 2022 Jun; 31(2):206-214. PubMed ID: 35574617
[TBL] [Abstract][Full Text] [Related]
2. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Polyzos SA; Aronis KN; Kountouras J; Raptis DD; Vasiloglou MF; Mantzoros CS
Diabetologia; 2016 Jan; 59(1):30-43. PubMed ID: 26407715
[TBL] [Abstract][Full Text] [Related]
3. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA.
Campbell PT; VanWagner LB; Colangelo LA; Lewis CE; Henkel A; Ajmera VH; Lloyd-Jones DM; Vaughan DE; Khan SS
Liver Int; 2020 May; 40(5):1111-1120. PubMed ID: 32090434
[TBL] [Abstract][Full Text] [Related]
4. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Ismaiel A; Leucuta DC; Popa SL; Dumitrascu DL
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300193
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders.
Chang ML; Hsu CM; Tseng JH; Tsou YK; Chen SC; Shiau SS; Yeh CT; Chiu CT
J Gastroenterol Hepatol; 2015 Feb; 30(2):329-36. PubMed ID: 25091195
[TBL] [Abstract][Full Text] [Related]
6. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Jin R; Krasinskas A; Le NA; Konomi JV; Holzberg J; Romero R; Vos MB
Pediatr Obes; 2018 Jan; 13(1):23-29. PubMed ID: 27764892
[TBL] [Abstract][Full Text] [Related]
7. High parathyroid hormone level as a marker of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Jaroenlapnopparat A; Rittiphairoj T; Chaisidhivej N; Walker B; Charoenngam N
Diabetes Metab Syndr; 2023 Aug; 17(8):102827. PubMed ID: 37451113
[TBL] [Abstract][Full Text] [Related]
8. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.
Ismaiel A; Jaaouani A; Leucuta DC; Popa SL; Dumitrascu DL
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944706
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
10. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
[TBL] [Abstract][Full Text] [Related]
12. Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Zhou Z; Chen H; Ju H; Sun M
Lipids Health Dis; 2017 Sep; 16(1):180. PubMed ID: 28931435
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.
Kotani K; Watanabe J; Miura K; Gugliucci A
Molecules; 2021 Apr; 26(8):. PubMed ID: 33923656
[TBL] [Abstract][Full Text] [Related]
14. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
16. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
[TBL] [Abstract][Full Text] [Related]
17. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.
Pacifico L; Bezzi M; Lombardo CV; Romaggioli S; Ferraro F; Bascetta S; Chiesa C
World J Gastroenterol; 2013 Jul; 19(25):4007-14. PubMed ID: 23840146
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease.
Sookoian S; Castaño GO; Burgueño AL; Rosselli MS; Gianotti TF; Mallardi P; Martino JS; Pirola CJ
Atherosclerosis; 2010 Apr; 209(2):585-91. PubMed ID: 19896127
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles from periodontal pathogens regulate hepatic steatosis via Toll-like receptor 2 and plasminogen activator inhibitor-1.
Kim HY; Lim Y; Jang JS; Ko YK; Choi Y; Kim HH; Choi BK
J Extracell Vesicles; 2024 Jan; 13(1):e12407. PubMed ID: 38251423
[TBL] [Abstract][Full Text] [Related]
20. Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease.
Eriksen PL; Thomsen KL; Sørensen M; Vilstrup H; Hvas AM
Thromb Res; 2022 May; 213():9-15. PubMed ID: 35256195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
